These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30782662)

  • 21. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.
    Roy D; Dittmer DP
    Am J Pathol; 2011 Oct; 179(4):2108-19. PubMed ID: 21819957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hippuristanol reduces the viability of primary effusion lymphoma cells both in vitro and in vivo.
    Ishikawa C; Tanaka J; Katano H; Senba M; Mori N
    Mar Drugs; 2013 Sep; 11(9):3410-24. PubMed ID: 24018901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.
    Ueno M; Kariya R; Sittithumcharee G; Okada S
    Phytomedicine; 2021 May; 85():153545. PubMed ID: 33799222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.
    Pourdehnad M; Truitt ML; Siddiqi IN; Ducker GS; Shokat KM; Ruggero D
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11988-93. PubMed ID: 23803853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Yamamoto T; Kanaya N; Somlo G; Chen S
    Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.
    Mazan-Mamczarz K; Peroutka RJ; Steinhardt JJ; Gidoni M; Zhang Y; Lehrmann E; Landon AL; Dai B; Houng S; Muniandy PA; Efroni S; Becker KG; Gartenhaus RB
    Cell Commun Signal; 2015 Mar; 13():15. PubMed ID: 25849580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
    Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
    Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.
    Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M
    Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.
    Boulanger E; Afonso PV; Yahiaoui Y; Adle-Biassette H; Gabarre J; Agbalika F
    Am J Transplant; 2008 Mar; 8(3):707-10. PubMed ID: 18261181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.
    Heinzen D; Divé I; Lorenz NI; Luger AL; Steinbach JP; Ronellenfitsch MW
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
    Petrossian K; Nguyen D; Lo C; Kanaya N; Somlo G; Cui YX; Huang CS; Chen S
    Breast Cancer Res Treat; 2018 Aug; 170(3):499-506. PubMed ID: 29623577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.
    Kang MH; Reynolds CP; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Aug; 61(8):1486-9. PubMed ID: 24623675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells.
    He M; Tan B; Vasan K; Yuan H; Cheng F; Ramos da Silva S; Lu C; Gao SJ
    J Pathol; 2017 Jul; 242(3):309-321. PubMed ID: 28393364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
    Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
    J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
    Li C; Cui JF; Chen MB; Liu CY; Liu F; Zhang QD; Zou J; Lu PH
    Cancer Biol Ther; 2015; 16(1):34-42. PubMed ID: 25692620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
    Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
    J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
    Waetzig R; Matthes M; Leister J; Penkivech G; Heise T; Corbacioglu S; Sommer G
    Int J Med Sci; 2021; 18(1):137-149. PubMed ID: 33390782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
    Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
    Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
    Rubens JA; Wang SZ; Price A; Weingart MF; Allen SJ; Orr BA; Eberhart CG; Raabe EH
    Neuro Oncol; 2017 Oct; 19(10):1361-1371. PubMed ID: 28582547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.